Excerpt from selegiline.com about EMSAM® (transdermal selegiline):
Related Articles/Links:
Transdermal Patch Could Herald Renewed Popularity for MAOIs
Future Drug Treatments for Depression, Anxiety, Sleep Disorders, and Psychosis
In December 2004, pharmaceutical firms Bristol-Myers Squibb and Somerset Pharmaceuticals announced they had entered into an agreement to distribute and commercialize EMSAM, the first transdermal treatment for major depression. If the FDA permits, the patch will be marketed in 2005 for both acute and long-term depressive disorder. The FDA's EMSAM "approvable" letter of February 2004 indicated that the efficacy data supported granting a product license. Such approval is by no means a foregone conclusion. It is claimed that EMSAM's pharmacokinetic and pharmacodynamic properties promote the inhibition of MAO-A and MAO-B in the CNS while avoiding significant inhibition of intestinal and liver MAO-A enzyme; but labeling discussions will inevitably focus on the prudence of tyramine dietary restrictions.
Related Articles/Links:
Transdermal Patch Could Herald Renewed Popularity for MAOIs
Future Drug Treatments for Depression, Anxiety, Sleep Disorders, and Psychosis